Matching Items (2)
Filtering by
- Member of: Barrett, The Honors College Thesis/Creative Project Collection
- Resource Type: Text
Description
Traumatic brain injury (TBI) is a leading cause of injury related death in the United States. The complexity of the injury environment that follows TBI creates an incomplete understanding of all the mechanisms in place to regulate chemotactic responses to TBI. The goal of this project was to develop a predictive in silco model using diffusion and autocrine/paracrine signaling specific to stromal cell derived factor-1α (SDF-1α) gradient formation after TBI and compare this model with in vivo experimental data. A COMSOL model using Fickian diffusion and autocrine/paracrine reaction terms was generated to predict the gradient formation observed in vivo at three physiologically relevant time points (1, 3, and 7 days). In vivo data was gathered and analyzed via immunohistochemistry and MATLAB. The spatial distribution of SDF-1α concentration in vivo more consistently demonstrated patterns similar to the in silico model dependent on both diffusion and autocrine/paracrine reaction terms rather than diffusion alone. The temporal distribution of these same results demonstrated degradation of SDF-1α at too rapid a rate, compared to the in vivo results. To account for differences in behavior observed in vivo, reaction terms and constants of 1st-order reaction rates must be modulated to better reflect the results observed in vivo. These results from both the in silico model and in vivo data support the hypothesis that SDF-1α gradient formation after TBI depends on more than diffusion alone. Future work will focus on improving the model with constants that are specific to SDF-1α as well as testing methods to better control the degradation of SDF-1α.
ContributorsFreeman, Sabrina Louise (Author) / Stabenfeldt, Sarah (Thesis director) / Caplan, Michael (Committee member) / Harrington Bioengineering Program (Contributor) / Barrett, The Honors College (Contributor)
Created2016-05
Description
Neurological disorders are difficult to treat with current drug delivery methods due to their inefficiency and the lack of knowledge of the mechanisms behind drug delivery across the blood brain barrier (BBB). Nanoparticles (NPs) are a promising drug delivery method due to their biocompatibility and ability to be modified by cell penetrating peptides, such as transactivating transciptor (TAT) peptide, which has been shown to increase efficiency of delivery. There are multiple proposed mechanisms of TAT-mediated delivery that also have size restrictions on the molecules that can undergo each BBB crossing mechanism. The effect of nanoparticle size on TAT-mediated delivery in vivo is an important aspect to research in order to better understand the delivery mechanisms and to create more efficient NPs. NPs called FluoSpheres are used because they come in defined diameters unlike polymeric NPs that have a broad distribution of diameters. Both modified and unmodified 100nm and 200nm NPs were able to bypass the BBB and were seen in the brain, spinal cord, liver, and spleen using confocal microscopy and a biodistribution study. Statistically significant differences in delivery rate of the different sized NPs or between TAT-modified and unmodified NPs were not found. Therefore in future work a larger range of diameter size will be evaluated. Also the unmodified NPs will be conjugated with scrambled peptide to ensure that both unmodified and TAT-modified NPs are prepared in identical fashion to better understand the role of size on TAT targeting. Although all the NPs were able to bypass the BBB, future work will hopefully provide a better representation of how NP size effects the rate of TAT-mediated delivery to the CNS.
ContributorsCeton, Ricki Ronea (Author) / Stabenfeldt, Sarah (Thesis director) / Sirianni, Rachael (Committee member) / Harrington Bioengineering Program (Contributor) / Barrett, The Honors College (Contributor)
Created2016-05